Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

6
Clinical Applications
of Pharmacogenomics
in Cancer Therapy
Mario Listiawan, Max Feng, and Xiaodong Feng
CONTENTS
Key Concepts.......................................................................................................... 144
Introduction............................................................................................................. 144
PGx Biomarkers for Toxicities Associated with Cancer Therapy........................... 146
Patient Case 1.......................................................................................................... 153
UGT1A1 and Irinotecan..................................................................................... 153
Patient Case 2.......................................................................................................... 157
TPMT Polymorphisms and 6-MP...................................................................... 157
TPMT Polymorphisms and Cisplatin................................................................. 158
Patient Case 3.......................................................................................................... 159
Dihydropyrimidine and 5-FU............................................................................. 159
CYP PGx............................................................................................................ 160
Patient Case 4.......................................................................................................... 161
G6PD and Rasburicase and Dabrafenib............................................................. 162
Drug Transporter–Related Biomarkers.............................................................. 162
Patient Case 5.......................................................................................................... 163
Drug Target–Related Biomarkers....................................................................... 163
HER2 Blocking Monoclonal Antibody and Breast Cancer............................... 163
Patient Case 6.......................................................................................................... 165
ER/PR Receptors................................................................................................ 166
Patient Case 7.......................................................................................................... 166
EGFR Antagonist and Targeted Therapy for Cancer......................................... 167
Cetuximab and Panitumumab................................................................................. 168
Crizotinib and Ceritinib.......................................................................................... 169
A New Generation of the BCR-ABL TKIs............................................................. 170
BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations................ 171
MEK Inhibitor Trametinib................................................................................. 172
PD-1 Inhibitors................................................................................................... 172
Others................................................................................................................. 172
Conclusions and Future Perspectives...................................................................... 173
Study Questions...................................................................................................... 173
References............................................................................................................... 175
143